Navigation Links
Bellicum Pharmaceuticals Announces $4.5 Million in New Funding

HOUSTON, Oct. 27 /PRNewswire/ -- Bellicum Pharmaceuticals, Inc. today announced $4.5 million in Series A and Convertible Note funding. The new funds will be used to complete the company's ongoing Phase I/IIa trial of BP-GMAX-CD1 in patients with advanced, androgen independent prostate cancer, and to prepare for Phase IIb trials. The company anticipates reporting initial results of the Phase I/IIa trial in mid 2010.

The new funding brings the total raised to date to $8.5 million, including $1.45 million from the Texas Emerging Technology Fund, $6.8 million from angel investors, and additional seed capital from founders. The $6.8 million in angel funding includes $4.3 million as Series A and $2.5 million as a Note convertible into Series A.

Bellicum Chief Executive Officer Tom Farrell stated, "It is particularly gratifying to raise sufficient funds in this challenging economic environment to advance beyond our next significant milestone, which is demonstrating clinical proof of principle for our core vaccine technology." Bellicum Founder, President & Chief Medical Officer Kevin M. Slawin, M.D., added, "Thanks to the support of our current and new investors, we are now in a strong position to realize the significant potential of our lead product to positively impact the lives of men living with prostate cancer."

About Bellicum Pharmaceuticals

Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum's novel approach is to control the signaling pathways that regulate the immune response, thereby generating potent, durable antigen-specific immunity. The company's lead product, BP-GMAX-CD1, a genetically modified, pharmacologically regulated autologous vaccine, is in clinical development for patients with advanced, androgen independent prostate cancer. The company owns or has in-licensed certain key technologies, and Chief Executive Officer Thomas J. Farrell has assembled a team of seasoned clinical, regulatory, quality and CMC consultants to advance product candidates through human clinical trials. For more information, visit

SOURCE Bellicum Pharmaceuticals, Inc.

SOURCE Bellicum Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Acquires Huxley Pharmaceuticals, Inc.
2. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
3. Transdel Pharmaceuticals to Webcast Presentation at 4th Annual BIOCOM Investor Conference
4. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
5. Quark Pharmaceuticals Expands International Patent Protection for Compounds Targeting the RTP801 Gene
6. Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009
7. Potentia Pharmaceuticals Enters into Licensing and Purchase Option Agreements with Alcon
8. NGM Biopharmaceuticals Appoints Dr. Arthur D. Levinson, Former Genentech CEO, to its Board of Directors
9. Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer
10. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the BIOCOM Investor Conference in San Diego on October 27, 2009
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
Breaking Medicine Technology:
(Date:6/26/2016)... Viejo, California (PRWEB) , ... June 26, 2016 , ... ... Final Cut Pro X. , "Film editors can give their videos a whole new ... said Christina Austin - CEO of Pixel Film Studios. , ProSlice Levels contains ...
(Date:6/25/2016)... ... 2016 , ... Austin residents seeking Mohs surgery services, can now turn to ... Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to ... fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of ...
(Date:6/25/2016)... City, Oklahoma (PRWEB) , ... June 25, 2016 ... ... helping both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic ... the Oklahoma City area —Johnson is one of the first doctors to perform ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
Breaking Medicine News(10 mins):